Concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm: a case report and literature review by Yoshie Kadota et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Kadota et al. World Journal of Surgical Oncology 2013, 11:75
http://www.wjso.com/content/11/1/75CASE REPORT Open AccessConcomitant pancreatic endocrine neoplasm and
intraductal papillary mucinous neoplasm: a case
report and literature review
Yoshie Kadota1, Masahiro Shinoda1*, Minoru Tanabe1, Hanako Tsujikawa2, Akihisa Ueno3, Yohei Masugi2,
Go Oshima1, Ryo Nishiyama1, Masayuki Tanaka1, Kisho Mihara1, Yuta Abe1, Hiroshi Yagi1, Minoru Kitago1,
Osamu Itano1, Shigeyuki Kawachi1, Koichi Aiura4, Akihiro Tanimoto3, Michiie Sakamaoto2 and Yuko Kitagawa1Abstract
We report a case of concomitant pancreatic endocrine neoplasm (PEN) and intraductal papillary mucinous
neoplasm (IPMN). A 74-year-old man had been followed-up for mixed-type IPMN for 10 years. Recent magnetic
resonance images revealed an increase in size of the branch duct IPMN in the pancreas head, while the dilation of
the main pancreatic duct showed minimal change. Although contrast-enhanced computed tomography and
magnetic resonance imaging did not reveal any nodules in the branch duct IPMN, endoscopic ultrasound indicated
a suspected nodule in the IPMN. A malignancy in the branch duct IPMN was suspected and we performed pylorus-
preserving pancreatoduodenectomy with lymphadenectomy. The resected specimen contained a cystic lesion, 10 x
10 mm in diameter, in the head of the pancreas. Histological examination revealed that the dilated main pancreatic
duct and the branch ducts were composed of intraductal papillary mucinous adenoma with mild atypia. No
evidence of carcinoma was detected in the specimen. Incidentally, a 3-mm nodule consisting of small
neuroendocrine cells was found in the main pancreatic duct. The cells demonstrated positive staining for
chromogranin A, synaptophysin, and glucagon but negative staining for insulin and somatostatin. Therefore, the 3-
mm nodule was diagnosed as a PEN. Since the mitotic count per 10 high-power fields was less than 2 and the Ki-
67 index was less than 2%, the PEN was pathologically classified as low-grade (G1) according to the 2010 World
Health Organization (WHO) criteria. Herein, we review the case and relevant studies in the literature and discuss
issues related to the synchronous occurrence of the relatively rare tumors, PEN and IPMN.
Keywords: Pancreatic endocrine neoplasm, Intraductal papillary mucinous neoplasmBackground
Pancreatic endocrine neoplasm (PEN) and intraductal
papillary neoplasm (IPMN) are both relatively rare tumors
among the primary pancreatic neoplasms, with reported
frequencies of approximately 0.4 per 100,000 and 1 per
100,000, respectively [1,2]. There have been only a few pub-
lished reports of cases in which PEN and IPMN were
present concomitantly [3-10]. We encountered a rare case
who underwent pancreatoduodenectomy for pancreas head
IPMN and whose postoperative pathological examination
revealed the existence of concomitant PEN. We present* Correspondence: masa02114@yahoo.co.jp
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reproduction in any medium, provided the orthis case and discuss issues related to the prevalence and
tumorigenesis based on a review of published literature.
Case presentation
A 74-year-old man was admitted to our hospital for the
examination of IPMN in the pancreas head. A cystic le-
sion, 6 mm in diameter, in the pancreas head was ini-
tially revealed when he underwent ultrasonography for a
routine checkup for fatty liver 10 years prior. Magnetic
resonance imaging revealed the cystic lesion and a
slightly dilated main pancreas duct (6 mm). The patient
was diagnosed with mixed-type (both main and branch
pancreatic ducts involved) IPMN and has been carefully
followed-up by magnetic resonance imaging every six
months for the last 10 years. The most recent magneticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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second most recent images, in the size of the IPMN
(that is, an increase from 8 mm to 12 mm) in the pan-
creatic head, while the dilation (6 mm) of the main pan-
creatic duct showed minimal change (axial image in
Figure 1A and cholangiopancreatography in Figure 1B).
The findings in the branch duct IPMN showed discrepant
results with different imaging modalities. While contrast-
enhanced computed tomography (Figure 1C) and mag-
netic resonance imaging did not show any nodules in
the IPMN, endoscopic ultrasound revealed a suspected
nodule (6 mm). The tumor markers carcinoembryonic
antigen (CEA), carbohydrate antigen 19–9 (CA19-9), and
DUPAN-2 were all within normal limits. Because there
was an increase in the size of the branch duct IPMN, and a
preoperative endoscopic ultrasound suggested the existence
of a nodule in the IPMN, a malignancy in the branch duct
IPMN was suspected and we performed pylorus-preserving
pancreatoduodenectomy (PpPD) with lymphadenectomy
for diagnostic and therapeutic purposes. The postoperative
course was uneventful and the patient was discharged on
post-operative Day 29 and has been alive for 18 months.
In the resected specimen, a dilated main pancreas duct,
6 mm in size, and a cluster of multiple dilated branch pan-
creas ducts were seen (Figure 2A). Histological examin-
ation revealed that both the main and branch pancreas
ducts were composed of intraductal papillary mucinous
adenoma with mild atypia (Figure 2B, C). Therefore, we
diagnosed this patient as having mixed-type IPMN. Inci-
dentally, a 3-mm nodule of endocrine cells was found in
the IPMN lesion in the main pancreas duct (Figure 2B, D).
Since the cells demonstrated positive staining for
chromogranin A and synaptophysin (Figure 2E, F), the
nodule was diagnosed as a PEN. The cells also showedMPD
BPD
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Figure 1 Preoperative imaging diagnoses. A) Magnetic resonance imag
rectangle is illustrated as an inset in the lower right. A black curved line in
illustrated as a cluster of gray areas, is seen around the main pancreas duc
(BPD) and has been diagnosed as branch intraductal papillary mucinous ne
The image is illustrated as an inset in the lower right. Black lines in the illus
gallbladder. The main pancreatic duct is dilated (7 mm) and also is marked
multiple dilated branch pancreas ducts (BPD), illustrated as a cluster of gray
tomography findings in the portal venous phase. A markedly curved main
by arrows) are seen in the pancreas head. No enhanced nodules are seenpositive staining for glucagon (Figure 2G), and negative
staining for insulin and somatostatin. The plasma levels of
glucagon, insulin and somatostatin had not been examined
preoperatively. Since the mitotic count per 10 high-power
fields was less than 2 and the Ki-67 index was less than 2%
(Figure 2H), the PEN was pathologically classified as a
well-differentiated neuroendocrine tumor and was low-
grade (G1) according to the 2000 and 2010 WHO criteria,
respectively [11,12]. We retrospectively assessed the pre-
operative images but did not find a nodule corresponding
to the PEN lesion. Regarding the nodule in the branch duct
IPMN, we also retrospectively assessed the preoperative
images and resected specimen but did not find evidence of
a nodule in the cluster of multiple dilated branch pancreas
ducts corresponding to the endoscopic ultrasound finding.
Thus, we recognize that such nodules can be misdiagnosed
or over-diagnosed (that is, generate a false positive result)
by endoscopic ultrasound.
Discussion
Neuroendocrine tumors are neoplasms that arise from
cells of the endocrine and nervous systems. They can ori-
ginate within the pancreas and are quite distinct from the
usual form of pancreatic cancer, which arises in the exo-
crine pancreas. IPMN is a type of neoplasm that grows
within the pancreatic ducts and is characterized by the
production of thick mucinous fluid. These two disease
entities have been thought to be distinct and no
tumorigenetic associations between them have been
reported in the past. Therefore, the incidence of coexist-
ence of these rare neoplasms should be extremely low if
their individual incidences are simply multiplied. However,
Marrache et al. [4] reported that the prevalence of associ-
ation between these tumors was 2.8% at their instituteMPD
BPD
C
ing findings (axial, T2-weighted image). The image indicated by a
the illustration indicates the main pancreas duct (MPD). A cystic lesion,
t. This lesion is a cluster of multiple dilated branch pancreas ducts
oplasm. B) Magnetic resonance cholangiopancreatography findings.
tration indicate the main pancreas duct (MPD), the biliary tree and the
ly curved like an S-shape in the pancreas head. A lesion consisting of
areas, is seen in the pancreas head. C) Contrast-enhanced computed
pancreas duct and multiple dilated branch pancreas ducts (indicated




















Figure 2 Macroscopic and microscopic findings of the resected specimen. A) Macroscopic findings of the resected specimen. The pancreas
head was cut in the direction shown in the illustration. Because the main pancreas duct was markedly curved in the pancreas head, a proximal
section (pMPD) and a distal section (dMPD) are seen in the same section. A cross section of the intra-pancreatic bile duct is seen (indicated as
BD). In this section, one of the dilated branch pancreas ducts is seen (indicated as BPD). B) Microscopic findings of the resected specimen
(hematoxylin and eosin stain, a loupe observation of the rectangle in macroscopic finding above). Almost all epithelia of both the main and
branch pancreas ducts were composed of intraductal papillary mucinous adenoma with mild atypia. BPD and pMPD indicates dilated branch
pancreas duct and proximal main pancreas duct, respectively. There is a demarcated area (surrounded by arrows) consisting of endocrine tumor.
C) Microscopic findings of the intraductal papillary mucinous adenoma (x460 nm/pix). D) Microscopic findings of the neuroendocrine area (x460
nm/pix). E-G) Immunohistochemical examination of the endocrine cells was positive for chromogranin A (E), synaptophysin (F), and glucagon (G).
H) Immunohistochemical examination of Ki-67. The positivity rate was less than 2%.
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IPMN). Goh et al. [5] and Gill et al. [10] subsequently
reported prevalence rates of 4.6% (3 of 65 patients who
underwent surgery for a PEN or IPMN) and 3.8% (4 of
104 patients who underwent surgery for IPMN), respect-
ively. These studies suggest that occurrence of PEN and
IPMN is more frequent than expected in the past and
that potentially concomitant PEN and IPMN may be
underdiagnosed. We retrospectively reviewed previouspathological reports of 34 PENs and 40 IPMNs in the past
15 years in our institute, but found no reports of concomi-
tant PEN and IPMN in a total of 74 cases. Given the
present case, the incidence of concomitant PEN and
IPMN is 1.3% (1 of 75 patients who underwent surgery for
PEN or IPMN) in our institute, which seems lower than
the rates described above [3-5]. To determine the actual
incidence of synchronous occurrence, it will be necessary
to examine a large number of patients with PEN or IPMN







Surgery PEN IPMN Postoperative
outcomeLocation, size
(mm)
Pathology1 Location, size (mm),
type
Pathology2
1 (3) 51/M PEN DP Tail, 15 Islet cell tumor with nesidioblastosis Tail, ND, ND IPMH (intraductal papillary
mucinous hyperplasia)
ND
2 (4) 73/M IPMN and PEN DP Tail, 28 Potentially malignant Tail, ND, Branch Benign ND
3 (4) 40/F IPMN and PEN PD Head, 11 Benign Head, ND, Branch Benign ND
4 (4) 61/F IPMN DP Tail, 12 Benign Tail, ND, Mixed Borderline ND
5 (4) 55/F PEN PD Head, 30 Malignant (duodenal wall invasion,
peripancreatic lymph nodes metastases)
Head, ND, Mixed Benign ND
6 (4) 68/F IPMN and PEN DP Body, 18 Benign Body, ND, Mixed Benign ND
7 (4) 62/M IPMN PD Head, 20 Potentially malignant Head, ND, Mixed Malignant noninvasive ND
8 (5) 65/F IPMN TP Body, 2 Benign Head, Body, 40, Mixed Malignant invasive Disease-free, 10
months
9 (5) 66/M IPMN TP Tail, 5 Benign Entire, 150, Mixed Malignant invasive Alive, 70 months
10 (5) 58/M IPMN DP Tail, 8 Benign Tail, 18, Branch Borderline Alive, 5 months
11 (6) 72/F ND PD Head, 25 PDNC (resional lymph nodes metastases) Head, ND, ND Borderline malignant potential Died, 10 months
12 (7) 75/M IPMN PD Head, 35 WDNC (peripancreatic lymph nodes metastases) Head, 35, Mixed Moderately to poorly
differentiated adenocarcinoma
Died, 6 months
13 (8) 54/F ND PD Head, ND ND Head, 25, Branch Benign ND
14 (9) 59/F IPMN and PEN observation Body, 7.8 Benign Body, Tail, 10 the largest, Branch ND Alive, 12 months
15 (9) 55/F IPMN and PEN enucleation Head, 20 Low malignant potential Head, 5,6,7, Branch ND ND
16 (10) 67/M IPMN TP Head, 8 WDNT Diffuse, 20, Main Low grade dysplasia ND
17 (10) 72/F IPMN and PEN DP Tail, 16 WDNC (peripancreatic lymph nodes metastases) Body, 9, Branch Low grade dysplasia ND
18 (10) 72/F IPMN DP Body, 9 WDNT Body, 15, Branch Low grade dysplasia ND
19 (10) 76/F IPMN TP Head, 11 WDNT Head, 27, Branch Well differentiated
adenocarcinoma
ND
20 74/M IPMN PD Head, 3 WDNT/NET G1 Head, 10, Mixed Low grade dysplasia Alive, 12 months
1. Pathology of PEN is described according to WHO 2000 criteria, as this was used in all prior studies. As for the present case, the pathology of the PEN is described according to both WHO 2000 and 2010 criteria.
2. The pathology of IPMN is described according to criteria in prior studies [15]. As for the present case, the pathology of IPMN is described according to WHO 2010 criteria [16].
Branch, branch type IPMN; DP, distal pancreatectomy; G1, Neuroendocrine tumor G1; IPMN, intraductal papillary mucinous neoplasm; Main, main duct type IPMN; Mixed, mixed type IPMN; ND, not described; PD,
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the presence of concomitant PEN and IPMN.
Previous studies have discussed the tumorigenesis of
concomitant PEN and IPMN. There are two major
hypotheses: 1) one cell type in a unique tumoral process
could transdifferentiate into another cell type; and 2) two
cell types could arise from a common neoplastic progeni-
tor. The former hypothesis is supported by many investi-
gators. For example, Goh et al. noted that (i) the mean
age of concomitant patients (60 years) corresponded ap-
proximately with that of IPMN, while PEN occurs in
much younger patients, (ii) the dominant neoplasm was
IPMN in most of the patients, and (iii) diagnosed PENs
were of a non-functional nature in most of the patients,
based on published reports, which suggests that the PEN
component typically arises through transdifferentiation
from IPMN [5]. Terada et al. found that argentaffin-,
serotonin- and gastrin-secreting cells were present in
IPMN but not in normal pancreatic ductal cells, and they
suggested that IPMN has the potential for endocrine dif-
ferentiation [13]. Hashimoto et al. found positivity for
exocrine markers expressed on some endocrine tumor
cells in a case of mixed PEN and IPMN, and it was noted
that the endocrine tumor cells might transdifferentiate to
ductal tumor cells [7]. All the features above may be sug-
gestive of tumorigenesis, but is little better than specula-
tion. The present case was a 74-year-old man, who had
IPMN dominancy and showed positive glucagon staining
in the PEN; however, this case did not provide definitive
findings regarding tumorigenesis. We recognize that it is
very difficult to assess the tumorigenesis of concomitant
PEN or IPMN. It is important to not only assess patients
for concomitant PEN and IPMN but also to describe the
features with respect to tumorigenesis.
In a search of the PubMed database, we found 19 cases
with concomitant PEN and IPMN in eight articles (Table 1).
Together with our present case, there are 20 cases with
concomitant PEN and IPMN (7 males and 13 females,
mean age was 63.7 years old) described in the literature.
The locations of PEN and IPMN were not described in nine
cases, apparently distant in five cases (case no. 2, 3, 4, 5 and
7 in Table 1), and very close or mixed in the same tumor in
six cases (case no. 1, 6, 11, 12, 13 and the present case in
Table 1). The preoperative diagnosis was IPMN in 10 cases,
PEN in 2 cases, not described in 2 cases, and concomitant
PEN and IPMN in only 6 cases. In 6 of the 10 cases whose
preoperative diagnosis was IPMN, the size of the PEN was
less than 10 mm. The pathological features of PEN were
benign in 12 cases, potentially malignant in 3 cases, neuro-
endocrine carcinoma in 4 cases, and not described in 1
case. The mean tumor sizes (maximum and minimum) of
PEN depending on the pathological features were 9.2 (18,
2) mm in benign, 22.6 (28, 20) mm in potentially malignant,
and 26.5 (35, 16) mm in neuroendocrine carcinoma. Basedon these results from a review of the published literature,
concomitant PEN and IPMN is frequently diagnosed as
IPMN only and concomitant PEN goes undiagnosed due to
its small size. The tumor size of PEN may serve as a guide
for clinicopathological features irrespective of the existence
of concomitant IPMN [14]. Although post-operative
courses are not fully described in most cases, the prognoses
for cases of neuroendocrine carcinoma seem pessimistic.
It is important to determine whether the postoperative
course and ideal management of cases of concomitant
PEN and IPMN differ from that of cases of PEN only or
IPMN only. No definitive guidelines have been established
in previous case reports of concomitant PEN and IPMN
due to the small number of reported cases. Since there
have been no reports of cases with concomitant PEN and
IPMN in which both PEN and IPMN showed benign or
low-grade malignancy, but one or the other showed
oncologically aggressive behavior, we believe that there are
no synergistic effects between PEN and IPMN, and that
cases of concomitant PEN and IPMN should be managed
according to their respective natural histories. At the
present time, this suggestion is speculative and needs to be
validated based on a larger number of cases in the future.
Conclusion
In conclusion, we encountered a case of concomitant
PEN and IPMN. There have been some reports sug-
gesting that the occurrence of concomitant PEN and
IPMN has been underreported or undetected because of
lack of awareness of the potential for concomitance and
poor examination of specimens. It is important to re-
cognize the concomitant neoplasms and determine the
actual incidence of this occurrence. We hope that this
case presentation will serve as a stimulus for further
studies to identify concomitant PEN/IPMN and to better
understand the underlying mechanisms.
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